Oligonucleotide for inhibiting gene translation and application thereof

By designing a suppressor gene translation RNA for translation initiation factor and target gene mRNA, combining translation initiation factor and mRNA to prevent ribosome movement, the problem of inaccurate gene regulation and difficulty in detoxification in the existing technology is solved, and efficient Controllable gene expression inhibition.

CN118979039APending Publication Date: 2024-11-19CENT SOUTH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411192578.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing targeted inhibitory oligonucleotide therapy is difficult to achieve accurate and controllable regulation of genes, and there are problems such as off-target effects and saturation of enzyme-dependent degradation mechanisms, and the detoxification strategy is inconvenient.

Method used

Design an oligonucleotide that inhibits gene translation, including aptamers targeting translation initiation factors and binding regions that pair in reverse complementary pairing with the mRNA 5' non-coding region of the gene of interest, and a suppressor gene translation formed by covalent ligation. RNA can simultaneously combine the translation initiation factor and the mRNA of the target gene, fix the translation initiation factor, prevent ribosomes from moving, thereby inhibiting gene translation.

Benefits of technology

It achieves efficient and controllable gene expression inhibition, avoids enzyme-dependent degradation and off-target effects, provides a rapid detoxification pathway, and is suitable for the treatment and research of fine-tuning gene expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention belongs to the technical field of synthetic biology and biology, and particularly relates to oligonucleotide for inhibiting gene translation by using an aptamer of a targeted translation initiation factor and application of the oligonucleotide. The oligonucleotide for inhibiting gene translation comprises an aptamer aiming at a translation initiation factor, a connecting region and an mRNA binding region in reverse complementary pairing with a target gene mRNA 5'non-coding region, the connecting region is connected between the aptamer and the mRNA binding region. The oligonucleotide for inhibiting gene translation can target specific mRNA in cells and inhibit expression of the mRNA in the cells, compared with a traditional siRNA inhibition method, the efficiency is high, and the method does not depend on enzyme and does not have saturation and inhibition upper limit; meanwhile, the inhibition effect can be lost after a corresponding antidote is added, the poisoning reaction is avoided, the safety is good, the design is simple, and the success rate is high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of synthetic biology and biotechnology, and particularly relates to an oligonucleotide for inhibiting gene translation and an application thereof, which is used for targeted gene inhibition. Background Art

[0002] Gene therapy is the intentional regulation of the expression of specific genes in specific cells to treat or control pathological conditions. This regulation is achieved by introducing exogenous nucleic acids such as DNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides (ASO). It is based on different mechanisms, such as modifying problematic genes with therapeutic genes, silencing unwanted genes or transfecting therapeutic genes to treat diseases. Most oligonucleotides interact with their cognate target molecules through Watson-Crick base pairing, and drugs involving these methods are intended to reduce the levels of harmful gene products, such as viral or bacterial proteins or cellular proteins that promote disease. A small number of them (such as aptamers, gRNA, etc.) interact with proteins through their three-dimensional secondary structures. However, these oligonucleotide technologies also have some inherent disadvantages. Taking siRNA as an example, gene silencing by siRNA begins after siRNA internalization, and it is difficult to control the time and location of gene silencing. siRNA has many types of off-target effects, and some types of off-target effects cannot be eliminated by reducing the dose of siRNA; due to the mechanism of action of siRNA, siRNA rescue is mostly achieved by delivering exogenous target mRNA vectors or target-like mRNA competing siRNA. siRNA rescue is very difficult and not suitable for therapeutic environments. Technologies such as siRNA, ASO and CRISPR / Cas9 will lead to enzyme-dependent degradation of target mRNA, and usually there are problems such as mechanism saturation. Steric blocking oligonucleotides use steric hindrance to prevent organelles from entering pre-mRNA and mRNA, but will not degrade RNA. Through this mechanism, steric blocking oligonucleotides can redirect selective splicing, repair defective RNA, restore protein production or downregulate gene expression. In addition, since the activity of steric blocking oligonucleotides does not require the use of cellular enzymes, they can be chemically modified more extensively to improve their drug properties.

[0003] Prior art CN202110363626.9 proposes a polynucleotide containing a p53 nucleic acid aptamer, the polynucleotide includes a ribozyme, a linker, and a nucleic acid aptamer that can specifically bind to the p53 protein, and the linker is connected between the ribozyme and the nucleic acid aptamer. This invention first proposed and successfully connected the p53 aptamer to the nucleotide that can encode the ribozyme. Experiments have shown that the p53 aptamer sequence on the polynucleotide can bind to the p53 protein, mediate the self-cleavage of the ribozyme sequence, and thus regulate the translation of the target gene mRNA. Compared with traditional gene transcription regulatory factors, the aptamer ribozyme riboswitch has a simple structure, a concise regulatory method, a rapid response, and has the advantages of low immunogenicity, so it has good clinical application prospects. However, the sequence of the polynucleotide is long, and the cost of industrial synthesis is high; it depends on the designed regulatory system, and the targets that can be regulated are limited; it is difficult to control the amount of polynucleotides when expressed using plasmids as vectors. Summary of the invention

[0004] The purpose of the present invention is to provide an oligonucleotide capable of specifically inhibiting the expression of targeted mRNA and inhibiting gene translation and its application.

[0005] In order to achieve the above object, the technical solution of the present invention is as follows: An oligonucleotide for inhibiting gene translation, comprising an aptamer for a translation initiation factor, a linker region, and an mRNA binding region that is reverse complementary to the 5' non-coding region of a target gene mRNA; the linker region is connected between the aptamer and the mRNA binding region. The oligonucleotide can simultaneously bind to the translation initiation factor and the target gene mRNA, and fix the translation initiation factor on the 5'UTR of the target gene mRNA. When the complementary chain of the oligonucleotide for inhibiting gene translation competes with the target gene mRNA to cause RNA to fall off the target gene mRNA, the oligonucleotide for inhibiting gene translation loses its inhibitory effect.

[0006] In a preferred embodiment, the translation initiation factor includes any one of eIF1, eIF1A, eIF2α, eIF2β, eIF2γ, eIF2B, eIF3, eIF4A, eIF4E, eIF4G, eIF4B, eIF4H, eIF5, eIF5B and eIF6.

[0007] In one preferred embodiment, the eIF3 includes eIF3a, eIF3b, eIF3c, eIF3d, eIF3e, eIF3f, eIF3g, eIF3h, eIF3i, eIF3j, eIF3k, eIF3l and eIF3m.

[0008] In a preferred embodiment, the aptamer against the translation initiation factor comprises a DNA aptamer or an RNA aptamer against the translation initiation factor.

[0009] In one preferred embodiment, the aptamer for the translation initiation factor comprises any one of an RNA aptamer for eIF4G, a DNA aptamer for eIF4E, an RNA aptamer for eIF4E, and an RNA aptamer for eIF4A; Among them, RNA aptamers targeting eIF4G include: aptamer4: AAGUCAGUCGCAUUGGCCGAGCUGUCGCUCUGACCAACUGA (SEQ ID NO. 1); aptamer3: AAGCCAGUCGCAUUGGCCGAGCUGUCGCUCUGACCAACUGG (SEQ ID NO. 2); aptamer5: CACCUCCGACGCACAGUCGCAGGCUCGAAAGAGACUAAAUGC (SEQ ID NO.3); aptamer2:UCCAGACCCCAACAGACUCCAUAACUAAUAUGUCGCAAAA (SEQ ID NO.4); aptamer14:UCCGUAGAAACGCGUUAAGGUGAAAGUUUGAGGGCUCCUCA (SEQ ID NO.5); aptamer17: ACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.6); aptamer18: UGCGCATAGGAAUUGCUCUCAAAAAACUGGACAAAAUAAUUUACGGCCGAACGCUUGCUCCGCCCUCUCA (SEQ ID NO. 7); aptamer19:UCCGCGGCGCCAUCUCAUGUUUAGUUGUCCUAUGUCGAGC (SEQ ID NO.8); DNA aptamers targeting eIF4E include: aptamer1:TGAGTAGTCAGGGATCAGTGCGGTTTCGTGATGG (SEQ ID NO.9); aptamer2:AATGAGATTCGGCAAGACCCGTCTTATTACAAC(SEQ ID NO.10); aptamer3:ATGCGTTTGAAGTTGCCCCGGAAGTAGGTTTTG(SEQ ID NO.11); aptamer4:AATGGGATGGAATTATTGTGTATTGATGACGAT(SEQ ID NO.12); aptamer5:TGTGGAGGTGGTTGGGGGTTCCGGTGGGGGGGG(SEQ ID NO.13); aptamer6:AGGTGGGAGGGTGGGGGTGGGAATGGGGGTTCA(SEQ ID NO.14); aptamer7:TATCGCAAGGCTATGGATCGCAATTCAGTGGC(SEQ ID NO.15); aptamer8: TTGGTTGGAGGTGGTGGGGGCCGGGGGGGGGGA(SEQ ID NO.16); aptamer9:GAGGGTGGTAAGTGTCTAAAGCCAGTTCTAGCG(SEQ ID NO.17); aptamer10:GCTAGTTGCAGCTATACAACGTAACGTTATGTG(SEQ ID NO.18); aptamer11:GTTAGGCTGGGATGTCTGGGCTTCGCGGCAGTA(SEQ ID NO.19); aptamer12:GATGTACAACCTTTTTTACCGAGAACACGGTGG(SEQ ID NO.20); The eIF4E transcription factor: aptamer1: GGGAGACAAGAAUAAAACGCUCAAUGUUCAACCAGAGUGAAACCACUAACGGGUCAGAGCCCCUUCGACAGGAGGCUCACAACAGGC(SEQ ID NO.21); aptamer2: GGGAGACAAGAAUAAACGCUCAAGCCAGAGCAACAACCUUCCGAGCCGCGGGAUAAAACCGAGUUCGACAGGAGGCUCACAACAGGC (SEQ ID NO. 22); RNA aptamers targeting eIF4A include: Aptamer21-short: GGAGAUCGCACUCCAUGUGAGUGAGGCCGAAACAUAGAUUCGACAGGAGGCUCACA (SEQ ID NO. 23).

[0010] RNA aptamers for eIF4A are disclosed in the prior art AKIHIRO OGURO, OHTSU TAKASHI, SVITKINYURI-V, et al. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis[J]. RNA, 2003, 9(4): 394-407.

[0011] RNA aptamers for eIF4E are disclosed in the prior art KIYOTAKA MOCHIZUKI, OGURO AKIHIRO, OHTSU TAKASHI, et al. High affinity RNA for mammalian initiation factor 4Einterferes with mRNA-cap binding and inhibits translation[J]. RNA, 2005, 11(1): 77-89.

[0012] DNA aptamers for eIF4E are disclosed in the prior art Wei-Mei Guo, Kong Kiat-Whye, BrownChristopher-John, et al. Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing[J].Molecular Therapy - Nucleic Acids, 2014, 3e217.

[0013] RNA aptamers for eIF4G are disclosed in the prior art Shin Miyakawa, Oguro Akihiro, OhtsuTakashi, et al. RNA aptamers to mammalian initiation factor 4G inhibit cap-dependent translation by blocking the formation of initiation factorcomplexes[J]. RNA, 2006, 12(10): 1825-1834.

[0014] In one preferred embodiment, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA includes: the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a continuous 8-20 base sequence in the mRNA that is reverse complementary to the 5' non-coding region of the target gene mRNA.

[0015] In one preferred embodiment, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is an 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA expressed by the plasmid pEGFP-N1; its sequence is preferably any one of GGAUCUGA, UAGCGGAUCUGA (SEQ ID NO.25), GCGCUAGCGGAUCUGA (SEQ ID NO.26), UUCGAAGCUUGA (SEQ ID NO.27), and GGUGGAUCCCGG (SEQ ID NO.28).

[0016] In a preferred embodiment, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA expressed by the plasmid pcDNA3.1-EGFP-PURO; the sequence is preferably CCAGUAAGCAGU (SEQ ID NO. 29).

[0017] In a preferred embodiment, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA encoding the cyclinD1 protein; the sequence is preferably CUCGCUGCUACU (SEQ ID NO. 30).

[0018] In a preferred embodiment, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA encoding the survivin protein; the sequence is preferably GCGGUUAAUGGC (SEQ ID NO.31).

[0019] In a preferred embodiment, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA encoding the Bcl-2 protein; the sequence is preferably CGCUAGAAGCCC (SEQ ID NO. 32).

[0020] In a preferred embodiment, the sequence of the connecting region is A, G, C, U, AA, AG, AU, AC, UU, UA, UG, UC, CC, CA, CG, CU, GG, GU, GC, GA, UUU, UUA, UUG, UUC, UAA, UAC, UAG, UAU, UGA, UGC, UGG, UGU, UCA, UCC, UCU, UCG, AAA, AAU, AAG, AAC, AUU, AUC, AUG, AUA, AGU, AGC, AGG, AGA, ACU, ACC, ACA, ACG, GGG, GGA, GGU, GGC, GAA, GAC, GAU, GAG, GUA, GUC, GUU, GUG, G Any of CA, GCC, GCG, GCU, CCC, CCA, CCG, CCU, CAA, CAU, CAG, CAC, CGA, CGU, CGG, CGC, CUA, CUU, CUC, CUG.

[0021] The purpose of introducing linkers into oligonucleotides is to establish a distance between oligonucleotides to avoid steric hindrance, reduce adverse interactions between groups, etc. The connection between oligonucleotides can be covalent or non-covalent, such as PC linker, spacer C3, etc. Considering the cost of synthesis and the simplicity of design, the present invention chooses to use oligonucleotides of the same nature for covalent connection.

[0022] Based on the same inventive concept, the present invention also claims protection for a construct containing the oligonucleotide for inhibiting gene translation.

[0023] Based on the same inventive concept, the present invention also claims to protect an expression system, which contains the oligonucleotide for inhibiting gene translation.

[0024] Based on the same inventive concept, the present invention also claims protection for a reagent composition comprising the oligonucleotide for inhibiting gene translation, and / or the construct, and / or the expression system in combination with a pharmaceutically acceptable excipient.

[0025] Based on the same inventive concept, the present invention also claims to protect the use of the oligonucleotide for inhibiting gene translation, and / or the construct, and / or the expression system in preparing an agent for inhibiting the expression of a targeted gene.

[0026] The present invention is further explained below: In order to overcome the difficulties of existing targeted inhibitory oligonucleotide therapy and achieve precise and controllable regulation of genes, the present invention is based on the aptamer for the translation initiation factor eIF4G protein screened by predecessors, and designs a nucleotide sequence translation inhibition RNA (oligonucleotides that inhibit gene translation, hereinafter referred to as RNA that inhibits gene translation), which consists of an RNA aptamer of eIF4G, an mRNA binding region (paired RNA to UTR) that is reverse complementary and paired with the 5' non-coding region (5'UTR) of the target gene mRNA, and a linker that combines the two. It is expected that the eIF4G protein and the target gene mRNA can be simultaneously bound to fix eIF4G on the 5'UTR of the mRNA. By changing the sequence of the paired RNA to UTR part, RNA that inhibits gene translation for different genes can be designed. When the complementary chain of the RNA that inhibits gene translation is used to compete with the mRNA to make the RNA fall off the mRNA, the RNA that inhibits gene translation loses its inhibitory effect.

[0027] As for eIF4G, the typical translation mode of eukaryotes is a ribosome scanning mechanism that depends on the m7G cap structure. The cap recognition protein eIF4E binds to the 5' cap and then recruits the scaffold protein eIF4G. eIF4G then recruits eIF4A and others to form the eIF4F complex, which recruits the 43S pre-initiation complex (PIC) to the mRNA. The complex moves along the mRNA to the AUG start codon to start translation. The eIF4G scaffold protein interacts with the poly (A) binding protein (PABP) to induce the cyclization of the mRNA to promote the direct recycling of the terminated ribosome to the start position of the mRNA. During the movement of the ribosome, if there is an RNA binding protein on the 5'UTR of the mRNA, it will inhibit the movement of the ribosome, resulting in specific, dose-dependent translation inhibition. Therefore, the inventors predict that fixing the translation initiation factor protein on the 5'UTR of the mRNA will, on the one hand, prevent the protein from binding to other proteins to form an effective eIF4F complex to inhibit translation, and on the other hand, it can inhibit translation due to steric hindrance to inhibit the movement of the ribosome. This regulation method is simple, efficient, stable and controllable, and may become a new method for regulating the expression of target genes. Aptamers are oligonucleotide sequences (DNA or RNA), usually oligonucleotide fragments obtained from nucleic acid molecule libraries using SELEX technology. Aptamers can fold to form specific three-dimensional spatial structures (such as G-quadruplexes, hairpins, etc.), and bind to target substances (such as proteins, etc.) with high affinity and high specificity. Starting from the biological mechanism of protein production, the present invention designs a short oligonucleotide sequence that can efficiently inhibit the expression of targeted genes without relying on the participation of enzymes in cells ( Figure 1 A). Such short oligonucleotide sequences are easy to design, highly effective, and simple to detoxify, and may become a new method for the regulation of target gene expression for treatment or research.

[0028] The beneficial effects of the present invention are: The gene translation inhibiting RNA designed by the present invention can target specific mRNA in cells and inhibit its expression in cells. It is more efficient than the traditional siRNA inhibition method, and the method does not rely on enzymes, and theoretically there will be no saturation and inhibition upper limit; at the same time, it can lose the inhibitory effect after adding the corresponding antidote, avoiding poisoning reaction, and is relatively safe. At present, there is no quick and convenient detoxification strategy for siRNA, and the gene translation inhibiting RNA does not destroy the targeted mRNA. The mRNA can resume translation after the gene translation inhibiting RNA is removed or after the gene translation inhibiting RNA is degraded, and is more suitable for the expression of genes that need to be finely regulated; the gene translation inhibiting RNA is simple to design and has a high success rate. Although siRNA has a mature modification strategy, the design is difficult and the success rate is low. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is a feasibility study of the solution of the present invention; wherein Figure 1 A is the action principle of RNA that inhibits gene translation. RNA that inhibits gene translation binds to mRNA, interrupting the translation initiation process of mRNA. Figure 1 B is the sequence simulation diagram and fluorescence observation results of four RNAs that inhibit gene translation. Figure 1 C is the WB result; Figure 1 D is Coomassie Brilliant Blue staining, which shows the effect of delivering RNA that inhibits gene translation on other non-acting target proteins; Figure 1 E is the effect on mRNA investigated by QPCR; Figure 1 F is the result of RNAPULLDOWN, which verifies that the designed RNA that inhibits gene translation binds to eIF4G protein and pseudo-mRNA; Figure 2 The effect of RNA that inhibits gene translation on GFP protein expression; Figure 2 A is a schematic diagram of the structure of RNA that inhibits gene translation; Figure 2 B is a Western Blot study of the effects of two RNAs that inhibit gene translation on GFP protein expression; Figure 2 C is a Western Blot study of the effect of paired RNA to UTR sequence on GFP protein expression; Figure 2 D is Western Blot study of the effect of aptamers on GFP protein expression; Figure 3 is the effect of various factors on the efficiency of RNA that inhibits gene translation; Figure 3 A is a Western Blot study of the effect of the number of complementary base pairs with mRNA on the efficiency of RNA that inhibits gene translation; Figure 3 B is a Western Blot study of the effect of nucleotide linker length on the efficiency of RNA that inhibits gene translation; Figure 3 C is a Western Blot study of the effect of the nucleotide distance from the 5' cap on the efficiency of RNA that inhibits gene translation; Figure 3 D is Western Blot study on the effect of action time on the efficiency of RNA that inhibits gene translation; Figure 4 Western Blot was used to study the inhibitory effect of RNA that inhibits gene translation on endogenous proteins; Figure 5 To study the effect of Bcl-2 and survivin protein reduction on apoptosis of two tumor cells by cell proliferation and flow cytometry. Figure 6Comparison of the effects of RNA and corresponding siRNA that inhibit gene translation of Bcl-2 and survivin. DETAILED DESCRIPTION

[0030] The present invention will be further described below in conjunction with embodiments.

[0031] All RNA / DNA chains and probes of the present invention were synthesized by Beijing Qingke Biotechnology Co., Ltd. All plasmids were purchased from Hunan Fenghui Biotechnology Co., Ltd. HEK 293T cells (including transfected cells), MDA-MB-231 cells, and A549 cells (purchased from the Advanced Research Center of Central South University) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (FBS) (Changsha Cellbox Biotechnology Co., Ltd.), and 1% penicillin-streptomycin sulfate (solarbio) at 37°C, 5% CO 2 Culture in a cell culture incubator. Example 1

[0032] (1) Design of translation inhibition RNA The translation inhibition RNA (hereinafter referred to as RNA for inhibiting gene translation) prepared in Example 1 is composed of an RNA aptamer of the translation initiation factor eIF4G, a protein required for translation initiation, an mRNA binding region (paired RNA to UTR) that is reverse complementary and paired with the 5' non-coding region (5'UTR) of the target gene mRNA, and a linker region (AAA is used as an example of the linker region) that combines the two, and can bind to the eIF4G protein and the target gene mRNA at the same time. By changing the sequence of the paired RNA to UTR part, RNA for inhibiting gene translation can be designed for different genes.

[0033] (2) Feasibility study In order to prove the feasibility of the designed RNA for inhibiting gene translation, the present invention designed different RNAs for inhibiting gene translation targeting GFP protein, and the sequence design is shown in Table 1.

[0034] Table 1 Different RNAs that inhibit gene translation against GFP protein RNA name Sequence (5'-3') pEGFP-N1-Apt2-RNA UAGCGGAUCUGAAAAUCCAGACCCCAACAGACUCCAUAACUAAUAUGUCGCAAAA (SEQ ID NO.33) pEGFP-N1-Apt14-RNA UAGCGGAUCUGAAAAUCCGUAGAAACGCGUUAAGGUGAAAGUUUGAGGGCUCCUCA (SEQ ID NO.34) pEGFP-N1-Apt17-RNA UAGCGGAUCUGAAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.35) pEGFP-N1-Apt19-RNA UAGCGGAUCUGAAAAUCCGCGGCGCCAUCUCAUGUUUAGUUGUCCUAUGUCGAGC (SEQ ID NO.36) pcDNA3.1-EGFP-Apt17-RNA CCAGUAAGCAGUAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.37) pcDNA3.1-EGFP-Apt17-cUTR CCAGUAAGCAGU (SEQ ID NO.38) pEGFP-N1-Apt17-cUTR UAGCGGAUCUGA(SEQ ID NO.39) Aptamer17 ACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.6) Aptamer2 UCCAGACCCCAACAGACUCCAUAACUAAUAUGUCGCAAAA (SEQ ID NO.4) Aptamer14 UCCGUAGAAACGCGUUAAGGUGAAAGUUUGAGGGCUCCUCA (SEQ ID NO.5) Aptamer19 UCCGCGGCGCCAUCUCAUGUUUAGUUGUCCUAUGUCGAGC (SEQ ID NO.8) Biotin-DNA probe Biotin-ATCAGATCCGCTAG (SEQ ID NO.40) The present invention comprehensively considers factors such as chain length and aptamer binding site to select 4 aptamers (aptamer 2, 14, 17, 19) that can bind to eIF4G but do not affect the function of eIF4G. The selected aptamers are aptamers that will not inhibit or retain the biological function of the translation initiation factor when binding to the translation initiation factor, and the site at which the aptamer binds to the translation initiation factor is not a site that needs to function when the translation initiation factor works. Four different RNAs (100 nM) that inhibit gene translation are designed and co-transfected into HEK 293T cells with a plasmid expressing GFP protein (pEGFP-N1, purchased from Hunan Fenghui Biotechnology Co., Ltd., 0.5 μg / ml) (pEGFP-N1-Apt2-RNA, pEGFP-N1-Apt14-RNA, pEGFP-N1-Apt17-RNA, pEGFP-N1-Apt19-RNA).

[0035] The transfection steps are as follows: The transfection reagent is Lipofectamine 2000 (Thermo Fisher Scientific). Taking a 6-well plate as an example, the cells are seeded in a 6-well plate the night before and transfected when the density is about 60%. Before transfection, the well plate medium is replaced with Opti-MEM (Thermo Fisher Scientific) medium, and the RNA chain and / or plasmid and 5µl Lipofectamine 2000 are dissolved in 100µl Opti-MEM medium respectively. After standing for 5 minutes, the two are mixed, and after standing for 15 minutes again, they are carefully added to the six-well plate. After 6 hours, it is replaced with DMEM complete medium to obtain transfected HEK 293T cells.

[0036] The transfected HEK 293T cells were used for the following studies: Using pEGFP-N1 plasmid (0.5µg / ml) + negative control (100nM) as the control group, the transfected HEK 293T cells were cultured for 48h and then the total protein was extracted. The expression of GFP protein was detected by Western Blot and observed under a fluorescence microscope.

[0037] The steps for total protein extraction are as follows: HEK 293T cells were collected after trypsin digestion, washed gently with cold PBS, and lysed using RIPA buffer (Beyotime) containing a protease inhibitor cocktail (Thermo Fisher Scientific) for 30 minutes, then centrifuged at 12,000 r for 10 minutes, and the supernatant was stored in a -80°C refrigerator.

[0038] The steps of Western Blot detection are as follows: Total protein concentration was measured using a BCA kit (Yazyme). After quantification, equal concentrations and volumes of each sample were separated by 10% SDS-PAGE gel (Vazyme). Subsequently, the sample was transferred to a 0.45µm PVDF membrane (millipore). Next, the membrane was blocked in 5% milk powder at room temperature for 1 hour, followed by washing with TBST three times for 10 minutes each time. After incubation with the primary antibody at 4°C overnight, the sample was washed with TBST for 10 minutes × 3 times, and then incubated with the HRP-labeled secondary antibody at room temperature for 2 hours, washed with TBST for 10 minutes × 3 times, and detected using ECLreagent (APExBIO) in a chemiluminescent imager (Bio-Rad). All antibodies were purchased from Wuhan Sanying Biotechnology Co., Ltd.

[0039] The steps for fluorescence microscopy observation are as follows: After culturing the transfected HEK 293T cells for 48 hours, wash the cells gently with PBS and add an appropriate amount of Hoechst staining solution (Biyuntian) to fully cover the sample to be stained. Usually, 1 ml of staining solution is added to each well of a six-well plate. Incubate in a cell culture incubator for 20-30 minutes. Discard the staining solution, wash with PBS 2-3 times, and then perform fluorescence detection. The results are as follows Figure 1 B and Figure 1 As shown in C. Figure 1 The results of Western Blot and fluorescence microscopy (ZIESS Axiom Obser 5) in B and 1C showed that RNAs that inhibit gene translation based on different aptamers can inhibit the expression of GFP protein. The different inhibition levels may be related to the different binding forces of aptamers to proteins. Among them, aptamer17 has the strongest inhibition level, and subsequent RNAs that inhibit gene translation are designed based on aptamer17.

[0040] Example 2 In order to explore the effect of RNA that inhibits gene translation on non-target proteins, the present invention transfected RNA that inhibits gene translation (100nM, Table 1) of 4 different aptamers into HEK 293T cells, and used untransfected cells as the control group. After 48 hours of culture, total protein was extracted, and protein expression was detected by Coomassie Brilliant Blue staining. The steps of transfection and total protein extraction were the same as in Example 1.

[0041] The steps of the Coomassie blue staining experiment are as follows: After the samples of equal mass were separated by 10% SDS-PAGE gel, the gel was peeled off the glass plate and placed in a plastic box. After the staining solution InstaBlue Protein Stain Solution (APExBIO) was inverted to mix, an appropriate amount of staining solution was poured into the plastic box, and the box was heated in a microwave oven until slightly steaming, and then transferred to a shaker and shaken for 2-5 min, and then the gel was photographed.

[0042] The results are as follows Figure 1 D. Figure 1 D Coomassie Brilliant Blue results showed that the content of different proteins in each group was basically the same, and RNA that inhibited gene translation had no effect on the expression of other proteins except GFP. Example 3 In order to explore the effect of RNA that inhibits gene translation on the level of GFP mRNA, the present invention co-transfected 4 different aptamers of RNA that inhibits gene translation (100nM) with a plasmid expressing GFP protein (0.5µg / ml) into HEK 293T cells, and used plasmid (0.5µg / ml) + negative control (100nM) as the control group. After culturing for 48h, total RNA was extracted for RT-qPCR to detect the expression of GFP mRNA. The transfection steps are the same as in Example 1. Total RNA was extracted from cells using TRIzol reagent (Invitrogen), and after extracting total cell RNA, the RNA was reverse transcribed into cDNA using the reverse transcription kit All-In-One 5X RT MasterMix (abcam). The reverse transcription program was 37°C 5min, 60°C 10min, 95°C 3min, and cooled to 4°C. cDNA was stored at -20°C.

[0043] 100 ng of cDNA and 0.8 µl of upstream and downstream primers, ArtiCan ATM SYBR qPCR Mix (tsingke) 10µl, RNA free water to 20µl, mixed, and placed in a real-time quantitative fluorescence PCR instrument for detection. The program was 95℃ 20s pre-denaturation, 95℃ 3s denaturation, 60℃ 10s extension, and 40 cycles. The GFP forward primer sequence was GACGTAAACGGCCACAAGTT, and the reverse primer sequence was AAGTCGTGCTGCTTCATGTG. β-actin was used for normalization, the β-actin forward primer sequence was CTCCATCCTGGCCTCGCT, and the reverse primer sequence was GCTGTCACCTTCACCGTTCC. Each group of experiments was repeated three times, and 2^ (-ΔΔCt) calculate.

[0044] The results are as follows Figure 1 As shown in E. Figure 1 E RT-qPCR results showed that RNA that inhibits gene translation did not lead to the degradation of GFP mRNA. Interestingly, the addition of RNA that inhibits gene translation also led to the accumulation of mRNA.

[0045] Example 4 In order to verify whether the designed RNA that inhibits gene translation can bind to mRNA and eIF4G protein after entering the cell, the present invention transfects the RNA that inhibits gene translation (100nM) into HEK 293T cells, and uses untransfected cells as the control group. After culturing for 24 hours, the cells are lysed (using RIPA buffer (Beyotime) containing a protease inhibitor mixture (Thermo Fisher Scientific) for 30 minutes, then lysed at 12000r, centrifuged for 10 minutes, and the supernatant is stored in a -80°C refrigerator) to obtain a cell lysate. The transfection steps are the same as in Example 1.

[0046] Total RNA was extracted from the cell lysate, and the extraction steps were the same as in Example 3. After the total RNA was extracted, an appropriate amount of RNaseInhibitor (APExBIO) was added for storage. After the Streptavidin Beads T3 magnetic beads (APExBIO) were washed, the biotinylated DNA probe (Beijing Qingke Biotechnology Co., Ltd.) was mixed with the magnetic beads and placed in a vortexer for rotation and incubation at room temperature for 1 hour. The magnetic beads without the addition of the DNA probe were used as the blank group, and the beads were washed again (the washing solution was 5mM Tris-HCl (pH 7.5), 0.5mMEDTA, 1 M NaCl) to obtain the magnetic bead-probe complex. The extracted total RNA was added to the magnetic bead-probe complex, and the cell extract without transfection of RNA that inhibited gene translation was used as the control group, incubated overnight at 4°C, and the magnetic beads were washed and stored at -20°C. The total RNA extract was diluted 10 times as the input group, and Western Blot was performed with the obtained product to detect eIF4G. The Western Blot detection steps are the same as in Example 1.

[0047] The results are as follows Figure 1 F. RNA pull down experiments were conducted to investigate whether the designed RNA that inhibits gene translation can bind to mRNA and eIF4G protein after entering cells. The mRNA chain was simulated by a DNA chain connected with biotin. The sequence design is shown in Table 1. The DNA chain was combined with streptavidin magnetic beads to capture RNA and the protein EIF4G connected to the RNA from the cell lysate. The EIF4G protein was detected by Western Blot. Figure 1F Western Blot results showed that only the cell lysate transfected with RNA that inhibits gene translation could specifically bind to the DNA chain, indicating that the designed RNA that inhibits gene translation could connect to mRNA and eIF4G protein, with a capture efficiency of 8.6%. Example 5 In order to verify the universality of RNA that inhibits gene translation, the present invention designed RNA that inhibits gene translation based on aptamer17 for GFP plasmids (pEGFP-N1, pcDNA3.1-EGFP-PURO) that produce different mRNAs. The sequence design is shown in Tables 1 and Figure 2 A, co-transfected with the corresponding plasmid (0.5µg / ml) at increasing concentrations (50nM, 100nM, 150nM) into HEK 293T cells, with plasmid (0.5µg / ml) + negative control (100nM) as the control group, and extracted total protein after 48h of culture and detected the expression of GFP protein by Western Blot. The steps of transfection, total protein extraction and Western Blot detection were the same as in Example 1. The results are shown in Figure 2 As shown in B, Figure 2 B is the Western Blot result showing that the two RNAs that inhibit gene translation both have a dose-dependent inhibitory effect on GFP protein. Example 6 In order to verify the dependence of RNA effect of inhibiting gene translation on the complete chain, the present invention co-transfected aptamer 17 and short RNA chains of paired RNA to UTR (pcDNA3.1-EGFP-Apt17-cUTR and pEGFP-N1-Apt17-cUTR in Table 1) with increasing concentrations (50nM, 100nM, 150nM) with corresponding plasmids (0.5µg / ml) into HEK 293T cells, and the sequence design is shown in Table 1. Plasmid (0.5µg / ml) + negative control (100nM) was used as the control group. After culturing for 48h, total protein was extracted and the expression of GFP protein was detected by Western Blot.

[0048] The steps of transfection, total protein extraction and Western Blot detection were the same as those in Example 1.

[0049] The results are as follows Figure 2 C and Figure 2 As shown in D. Figure 2 Western Blot results in C and D show that the aptamer and the two short RNAs that complementarily bind to mRNA have no effect on the expression of GFP from two different plasmids.

[0050] The above results show that the designed RNA for inhibiting gene translation is universal and can exert its effect on different mRNAs after replacing the paired RNA to UTR sequence. At the same time, its effect does not depend on the aptamer itself or the paired RNA to UTR sequence, but exerts an inhibitory effect as a whole. Example 7 Design and optimization of RNA that inhibits gene translation In order to achieve higher inhibition efficiency, the present invention optimizes the number of complementary pairing with mRNA bases, the length of the nucleotide linker, the nucleotide distance from the 5' cap, the nucleotide action time, and other conditions. The sequence optimization design sequence is shown in Table 2.

[0051] Table 2 Sequence optimization design sequence RNA name Sequence (5'-3') pEGFP-N1-8rp GGAUCUGAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.41) pEGFP-N1-12rp UAGCGGAUCUGAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.35) pEGFP-N1-16rp GCGCUAGCGGAUCUGAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.42) pEGFP-N1 -0A UAGCGGAUCUGAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.43) pEGFP-N1 -3A UAGCGGAUCUGAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.35) pEGFP-N1 -6A UAGCGGAUCUGAAAAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.44) pEGFP-N1-12A UAGCGGAUCUGAAAAAAAAAAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.45) pEGFP-N1-0nt UAGCGGAUCUGAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.35) pEGFP-N1-37nt UUCGAAGCUUGAAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.46) pEGFP-N1-74nt GGUGGAUCCCGGAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.47) The designed RNA (100 nM) that inhibits gene translation was co-transfected with plasmid (pEGFP-N1) (0.5 µg / ml) into HEK 293T cells, and total protein was extracted after 48 h of culture, and the expression of GFP protein was detected by Western Blot. The steps of transfection, total protein extraction and Western Blot detection were the same as those in Example 1.

[0052] The results are as follows Figure 3 shown. Figure 3 A is the optimization result of the number of complementary base pairs with mRNA. The RNAs that inhibit gene translation were designed with complementary base pairs of 8nt, 12nt, and 16nt with mRNA, respectively. It was shown that the best promotion effect was achieved when the number of complementary base pairs with mRNA was 12nt. Figure 3 B is the optimization result of the nucleotide linker length. The RNAs that inhibit gene translation were designed with nucleotide linker lengths of 0nt, 3nt, 6nt, and 12nt. It was shown that the inhibition effect was best when the linker length was 3nt. Figure 3 C is the nucleotide distance from the 5' cap. RNAs that inhibit gene translation were designed with nucleotide distances of 0nt, 37nt, and 74nt (approximately at the beginning, midpoint, and end of the entire 5'UTR) from the 5' cap. The results showed that the closer the nucleotide distance from the 5' cap, the better the inhibitory effect. Figure 3 D is the result of action time optimization. The expression of GFP was detected at 24h, 48h, and 72h, and the inhibition efficiency was calculated with the plasmid (0.5µg / ml) + negative control (100nM) as the control group as a reference. The results showed that the inhibition effect was best at 48h.

[0053] Example 8 Investigation of the inhibitory effect of endogenous proteins The present invention selected three tumor cell intracellular proteins, namely cyclin D1, Bcl-2, and survivin, and designed RNA chains that target and inhibit gene translation. The sequence design is shown in Table 3.

[0054] Table 3 Sequences of RNA chains that target and inhibit gene translation RNA Name Sequence (5’-3’) cyclinD1- RNA CUCGCUGCUACUAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.48) survivin- RNA GCGGUUAAUGGCAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.49) Bcl-2-RNA CGCUAGAAGCCCAAAACUCACUAUUUGUUUUCGCGCCCAGUUGCAAAAAGUGUCG (SEQ ID NO.50) survivin-siRNA1 GCAUUCGUCCGGUUGCGCU (SEQ ID NO.51) survivin-siRNA2 GGACCACCGCAUCUACA (SEQ ID NO.52) Bcl-2-siRNA1 GUGAAGUCAACAUGCCUGC (SEQ ID NO.53) Bcl-2-siRNA2 UUCGGCAUUAGGCCUUCCG (SEQ ID NO.54) The proteins were delivered into MDA-MB-231 cells and A549 cells by transfection at concentration gradients (0nM, 50nM, 100nM, 200nM). After 48h of culture, the total proteins were extracted and the expression of the corresponding proteins was detected by Western Blot.

[0055] The steps of transfection, total protein extraction and Western Blot detection were the same as in Example 1. The results are shown in Figure 4 shown. Figure 4 Western Blot results showed that the designed RNA that inhibits gene translation exerted a dose-dependent inhibitory effect on cyclin D1, Bcl-2, and survivin in two cell lines (MDA-MB-231 cells and A549 cells). Example 9 To verify the effect of protein inhibition on cells, RNAs targeting Bcl-2 and survivin that inhibit gene translation were co-delivered to MDA-MB-231 cells and A549 cells at concentration gradients (0 nM, 50 nM, 100 nM) by transfection, and CCK8 and flow cytometry were performed, respectively. The transfection steps were the same as in Example 1.

[0056] The steps of CCK8 detection (Cell Proliferation Assays) are as follows: RNA targeting Bcl-2 and survivin that inhibits gene translation was delivered to MDA-MB-231 cells and A549 cells by transfection at a concentration gradient (0nM, 100nM, 200nM), and replaced with complete DMEM 6h after transfection. At this time, the cells were digested with trypsin (gibco) and counted, and transferred to a 96-well plate at 2000 cells / well. After culturing for 0h, 24h, 48h, 72h, and 96h, the DMEM medium containing 10% CCK-8 reagent (APExBIO) was replaced and placed in an incubator for 2h. The absorbance was detected with a microplate reader (Tecaninfinite M200 PRO) at a detection wavelength of 450nm.

[0057] The steps of flow cytometry detection are as follows: The kit used was Annexin V-Alexa Fluor 647, Beijing Sizhengbai Biotechnology Co., Ltd. The binding buffer was diluted with deionized water at a ratio of 1:4 (4 ml binding buffer + 12 ml deionized water); the cells were digested and collected with EDTA-free trypsin (Gibco), the cells were washed twice with 4°C pre-cooled PBS, and the cells were resuspended with 250ul binding buffer to adjust the concentration to 1× 106 / ml; 100μl of the cell suspension was placed in a 5ml flow tube, 5μl AnnexinV / AlexaFluor647 and 10μl 20ug / ml propidium iodide solution were added, mixed and incubated at room temperature in the dark for 15 minutes; 400μl PBS was added to the reaction tube and analyzed by flow cytometry (FACS) (bd canto Ⅱ).

[0058] The results are as follows Figure 5 shown. Figure 5 The CCK8 results showed that the reduction of Bcl-2 and survivin proteins inhibited the proliferation of both tumor cells; Figure 5 The results of flow cytometry showed that the reduction of Bcl-2 and survivin proteins promoted the apoptosis of both tumor cells.

[0059] The steps of transfection, total protein extraction and Western Blot detection were the same as those in Example 1.

[0060] The operation of Survivin is the same as above.

[0061] The sequences of siRNAs are shown in Table 3.

[0062] The results are as follows Figure 6 shown. Figure 6 Western Blot results showed that the effect of RNA inhibiting gene translation of Bcl-2 and survivin was stronger than that of the corresponding siRNA.

[0063] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made within the scope of the claims of the present invention should fall within the scope of the claims of the present invention.

Claims

1. An oligonucleotide that inhibits gene translation, It is characterized in that It comprises an adapter targeting a translation initiation factor, a connection region and an mRNA binding region which is reversely complementary paired with a 5' non-coding region of a target gene mRNA; the connection region is connected between the adapter and the mRNA binding region.

2. The oligonucleotide for inhibiting gene translation according to claim 1, It is characterized in that The translation initiation factor includes any one of eIF1, eIF1A, eIF2α, eIF2β, eIF2γ, eIF2B, eIF3, eIF4A, eIF4E, eIF4G, eIF4B, eIF4H, eIF5, eIF5B and eIF6.

3. The oligonucleotide for inhibiting gene translation according to claim 2, It is characterized in that The eIF3 includes eIF3a, eIF3b, eIF3c, eIF3d, eIF3e, eIF3f, eIF3g, eIF3h, eIF3i, eIF3j, eIF3k, eIF3l and eIF3m.

4. The oligonucleotide for inhibiting gene translation according to claim 1, It is characterized in that The aptamer against the translation initiation factor includes a DNA aptamer or an RNA aptamer against the translation initiation factor.

5. The oligonucleotide for inhibiting gene translation according to claim 1, It is characterized in that The aptamer for the translation initiation factor includes any one of an RNA aptamer for eIF4G, a DNA aptamer for eIF4E, an RNA aptamer for eIF4E, and an RNA aptamer for eIF4A; Preferably, the RNA aptamer for eIF4G includes the sequence shown in SEQ ID NO.1-8; the DNA aptamer for eIF4E includes the sequence shown in SEQ ID NO.9-20; the RNA aptamer for eIF4E includes the sequence shown in SEQ ID NO.21-22; the RNA aptamer for eIF4A includes the sequence shown in SEQ ID NO.

23.

6. The oligonucleotide for inhibiting gene translation according to claim 1, It is characterized in that The mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a continuous 8-20 base sequence in the mRNA that is reverse complementary to the 5' non-coding region of the target gene mRNA; preferably, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA expressed by the plasmid pEGFP-N1; its sequence is preferably GGAUCUGA or any one of SEQ ID NO.25-28; preferably, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA expressed by the plasmid pcDNA3.1-EGFP-PURO; its sequence is preferably SEQ ID NO.29; preferably, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA expressed by the plasmid pcDNA3.1-EGFP-PURO; its sequence is preferably SEQ ID NO.29; preferably, The mRNA binding region that is reverse complementary to the 5' non-coding region is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA encoding the cyclinD1 protein; its sequence is preferably SEQ ID NO.30; preferably, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA encoding the survivin protein; its sequence is preferably SEQ ID NO.31; preferably, the mRNA binding region that is reverse complementary to the 5' non-coding region of the target gene mRNA is a 8-20 base sequence that is reverse complementary to the 5' non-coding region of the mRNA encoding the Bcl-2 protein; its sequence is preferably SEQ ID NO.

32.

7. The oligonucleotide for inhibiting gene translation according to any one of claims 1 to 6, It is characterized in that The sequence of the connecting region is A, G, C, U, AA, AG, AU, AC, UU, UA, UG, UC, CC, CA, CG, CU, GG, GU, GC, GA, UUU, UUA, UUG, UUC, U AA, UAC, UAG, UAU, UGA, UGC, UGG, UGU, UCA, UCC, UCU, UCG, AAA, AAU, AAG, AAC, AUU, AUC, AUG, AUA, AGU , AGC, AGG, AGA, ACU, ACC, ACA, ACG, GGG, GGA, GGU, GGC, GAA, GAC, GAU, GAG, GUA, GUC, GUU, GUG, GCA, G Any one of CC, GCG, GCU, CCC, CCA, CCG, CCU, CAA, CAU, CAG, CAC, CGA, CGU, CGG, CGC, CUA, CUU, CUC, CUG.

8. A construct, It is characterized in that The construct contains the oligonucleotide for inhibiting gene translation according to any one of claims 1 to 7.

9. An expression system, It is characterized in that The expression system contains the oligonucleotide for inhibiting gene translation according to any one of claims 1 to 7.

10. Use of the oligonucleotide for inhibiting gene translation according to any one of claims 1 to 7, and / or the construct according to claim 8, and / or the expression system according to claim 9 in the preparation of an agent for inhibiting target gene expression.